ECG Contrast Agents May Get Warnings Reduced After Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Post-marketing studies requested for Lantheus Medical Imaging's Definity and GE Healthcare's Optison appear to point to lower cardiopulmonary risks than FDA had suspected when it asked the companies to add boxed warnings to the product labels in 2007.